Question | Discussion | References | CME Credit

Case 3: References

  1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-35.
    [The following link will open in a new window. PubMed Abstract]
  2. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:S25-33.
    [The following link will open in a new window. PubMed Abstract]
  3. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-6.
    [The following link will open in a new window. PubMed Abstract]
  4. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44:2475-84.
    [The following link will open in a new window. PubMed Abstract]
  5. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75:4999-5008.
    [The following link will open in a new window. PubMed Abstract]
  6. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol. 2001;65:445-8.
    [The following link will open in a new window. PubMed Abstract]
  7. Demeter LM, Shafer RW, Meehan PM, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000;44:794-7.
    [The following link will open in a new window. PubMed Abstract]
  8. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis. 2000;181:904-11.
    [The following link will open in a new window. PubMed Abstract]
  9. Casado JL, Moreno A, Hertogs K, Dronda F, Moreno S. Extent and importance of cross-resistance to efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18:771-5.
    [The following link will open in a new window. PubMed Abstract]
  10. Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr. 20001;23:221-6.
    [The following link will open in a new window. PubMed Abstract]
  11. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18:835-8.
    [The following link will open in a new window. PubMed Abstract]
  12. Briones C, Soriano V, Dona C, Barreiro P, Gonzalez-Lahoz J. Can early failure with nevirapine be rescued with efavirenz? J Acquir Immune Defic Syndr. 2000;24:76-8.
    [The following link will open in a new window. PubMed Abstract]
  13. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
    [The following link will open in a new window.PubMed Abstract]
  14. Finzi D, Blankson J, Sliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-7.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 3 Question | Back to Discussion]

CME Credit | Back to Top